{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:28:58Z","timestamp":1792801738409,"version":"4.5.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Next Generation Flow (NGF) represents a gold standard for the evaluation of Minimal Residual Disease (MRD) in Multiple Myeloma (MM) patients at any stage of treatment. Although the assessment of MRD is still not universally employed in clinical practice, numerous studies have demonstrated the strength of MRD as a reliable predictor of long-term outcome, and its potential to supersede the prognostic value of CR. The possibility to acquire millions of events, in combination with the use of standard reagents and a good expertise in the analysis of rare populations, led to high chance of success and a sensitivity of 10<jats:sup>-6<\/jats:sup> that is superimposable to the one of Next Generation Sequencing molecular techniques. Some minor bias, correlated to the protocols applied, to the quality of samples and to the high heterogeneity of plasma cells phenotype, may be overcome using standard protocols and having at disposition personnel expertise for MRD analysis. With the use of NGF we can today enter a new phase of the quantification of residual disease, switching from the definition of \u201cminimal\u201d residual disease to \u201cmeasurable\u201d residual disease. This review takes account of the principle \u201cfriends and foes\u201d of Myeloma \u201cMeasurable\u201d Residual Disease evaluation by NGF, to give insights into the potentiality of this technique. The optimization of the quality of BM samples and the analytic expertise that permits to discriminate properly the rare pathologic clones, are the keys for obtaining results with a high clinical value that could be of great impact and relevance in the future.<\/jats:p>","DOI":"10.3389\/fonc.2022.1057713","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T07:02:58Z","timestamp":1669618978000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["\u201cFriends and foes\u201d of multiple myeloma measurable\/minimal residual disease evaluation by next generation flow"],"prefix":"10.3389","volume":"12","author":[{"given":"Paola","family":"Pacelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Raspadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bestoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00241","article-title":"Therapeutic advancements in multiple myeloma","volume":"4","author":"Gozzetti","year":"2014","journal-title":"Front Oncol"},{"key":"B3","article-title":"Multiple myeloma: Diagnosis and treatment","volume":"95","author":"Michels","year":"2017","journal-title":"Am Fam Physician"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50129","article-title":"Biology and therapy of multiple myeloma","volume":"210","author":"Joshua","year":"2019","journal-title":"Med J Aust"},{"key":"B5","unstructured":"HowlanderN\n            NooneAM\n            KrapchoM\n            MillerD\n            BrestA\n            YuM\n          Berthesda, MD, USANational Cancer InstituteSEER cancer statistics review, 1975-20182020"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.018","article-title":"Multiple myeloma treatment in real-world clinical practice: Results of a prospective, multinational, noninterventional study","volume":"18","author":"Mohty","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2052658","article-title":"Anti CD38 monoclonal antibodies for multiple myeloma treatment","volume":"18","author":"Gozzetti","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.350","article-title":"New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the international myeloma working group (IMWG)","volume":"28","author":"Ocio","year":"2014","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24753","article-title":"IgM myeloma: A multicenter retrospective study of 134 patients","volume":"92","author":"Castillo","year":"2017","journal-title":"Am J Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/1871524914999140818111514","article-title":"Novel agents in CNS myeloma treatment","volume":"14","author":"Gozzetti","year":"2014","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_159016","article-title":"Moving beyond autologous transplantation in multiple myeloma: Consolidation, maintenance, allogeneic transplant, and immune therapy","volume":"35","author":"Krishnan","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40487-021-00143-7","article-title":"Post-transplant maintenance treatment options in multiple myeloma","volume":"9","author":"Karam","year":"2021","journal-title":"Oncol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092277","article-title":"Improvement in post-autologous stem cell transplant survival of multiple myeloma patients: A long-term institutional experience","volume":"14","author":"Nunnelee","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072142","article-title":"Minimal residual disease in multiple myeloma: State of the art and future perspectives","volume":"9","author":"Mina","year":"2020","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00633-5","article-title":"MRD assessment in multiple myeloma: Progress and challenges","volume":"16","author":"Bertamini","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091451","article-title":"Steps towards a multiple myeloma cure","volume":"12","author":"Gozzetti","year":"2022","journal-title":"J Pers Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2021.116","article-title":"Drug resistance and minimal residual disease in multiple myeloma","volume":"5","author":"Gozzetti","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2021.02.003","article-title":"Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use","volume":"53","author":"Maclachlan","year":"2021","journal-title":"Pathology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21228","article-title":"Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting","volume":"90","author":"Arroz","year":"2016","journal-title":"Cytom B Clin Cytom"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21272","article-title":"Assessment of minimal residual disease in myeloma and the need for a consensus approach","volume":"90","author":"Rawstron","year":"2016","journal-title":"Cytom B Clin Cytom"},{"key":"B23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030120","article-title":"Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice","volume":"10","author":"Gozzetti","year":"2020","journal-title":"J Pers Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04634-5","article-title":"Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry","volume":"100","author":"Sato","year":"2021","journal-title":"Ann Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02615-z","article-title":"Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry","volume":"109","author":"Takamatsu","year":"2019","journal-title":"Int J Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"11218","DOI":"10.1038\/s41598-021-89761-9","article-title":"Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods","volume":"11","author":"Yoroidaka","year":"2021","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.820605","article-title":"The utility of euroflow MRD assessment in real-world multiple myeloma practice","volume":"12","author":"Turner","year":"2022","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16130","article-title":"Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma","volume":"186","author":"Bal","year":"2019","journal-title":"Br J Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4415\/ANN_21_04_05","article-title":"Measurable residual disease in multiple myeloma and in acute myeloid leukemia, an evolving topic","volume":"57","author":"Castelli","year":"2021","journal-title":"Ann Ist Super Sanita"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184582","article-title":"Multiparametric flow cytometry for MRD monitoring in hematologic malignancies: Clinical applications and new challenges","volume":"13","author":"Riva","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.801851","article-title":"Minimal residual disease assessment in multiple myeloma patients: Minimal disease with maximal implications","volume":"11","author":"Charalampous","year":"2022","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition","volume":"90","author":"Stetler-Stevenson","year":"2016","journal-title":"Cytom B Clin Cytom"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cpcy.66","article-title":"Immunophenotypic detection of measurable residual (Stem cell) disease using LAIP approach in acute myeloid leukemia","volume":"91","author":"Zeijlemaker","year":"2019","journal-title":"Curr Protoc Cytom"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/0300060518819637","article-title":"Clinically useful flow cytometry approach to identify immunophenotype in acute leukemia","volume":"47","author":"Ouyang","year":"2019","journal-title":"J Int Med Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25431","article-title":"Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance","volume":"94","author":"Sui","year":"2019","journal-title":"Am J Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/cpcy.73","article-title":"Acute myeloid leukemia minimal residual disease detection: The difference from normal approach","volume":"93","author":"Wood","year":"2020","journal-title":"Curr Protoc Cytom"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04580-2","article-title":"Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in b-ALL","volume":"100","author":"Das","year":"2021","journal-title":"Ann Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061714","article-title":"Measurable residual disease in acute myeloid leukemia using flow cytometry: A review of where we are and where we are going","volume":"9","author":"Dix","year":"2020","journal-title":"J Clin Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.121","article-title":"EuroFlow: Resetting leukemia and lymphoma immunophenotyping. basis for companion diagnostics and personalized medicine","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.112680","article-title":"Comments on EuroFlow standard operating procedures for instrument setup and compensation for BD FACS canto II, navios and BD FACS lyric instruments","volume":"475","author":"Glier","year":"2019","journal-title":"J Immunol Methods"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00001","article-title":"Clinical applications and future directions of minimal residual disease testing in multiple myeloma","volume":"10","author":"Oliva","year":"2020","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174136","article-title":"Circulating tumour cells, cell free DNA and tumour-educated platelets as reliable prognostic and management biomarkers for the liquid biopsy in multiple myeloma","volume":"14","author":"Allegra","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01040","article-title":"Circulating tumor cell burden as a component of staging in multiple myeloma: Ready for prime time","volume":"40","author":"Chakraborty","year":"2022","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061430","article-title":"Biological characterization and clinical relevance of circulating tumor cells: Opening the pandora's box of multiple myeloma","volume":"14","author":"Garc\u00e9s","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","article-title":"Circulating tumor cells: biology and clinical significance","volume":"6","author":"Lin","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-55947-6_5","article-title":"Flow cytometric methods for circulating tumor cell isolation and molecular analysis","volume":"994","author":"Bhagwat","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0883-0","article-title":"Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma","volume":"34","author":"Garc\u00e9s","year":"2020","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41375-019-0588-4","article-title":"Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination","volume":"34","author":"Garc\u00e9s","year":"2020","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194924","article-title":"Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma","volume":"13","author":"Puig","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2016.12.006","article-title":"A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates","volume":"442","author":"Delgado","year":"2017","journal-title":"J Immunol Methods"},{"key":"B61","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/cyto.b.20429","article-title":"Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses","volume":"76","author":"Loken","year":"2009","journal-title":"Cytom B Clin Cytom"},{"key":"B62","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11101872","article-title":"Harmonization of flow cytometric minimal residual disease assessment in multiple myeloma in centers of polish myeloma consortium","volume":"11","author":"Krzywdzi\u0144ska","year":"2021","journal-title":"Diagn (Basel)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21789","article-title":"Immunophenotypic heterogeneity of polytypic plasma cells and the impact on myeloma minimal residual disease detection by multiparameter flow cytometry","volume":"96","author":"Schouweiler","year":"2019","journal-title":"Cytom B Clin Cytom"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2012-200881","article-title":"Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma","volume":"65","author":"Liu","year":"2012","journal-title":"J Clin Pathol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqz153","article-title":"VS38 identifies myeloma cells with dim CD38 expression and plasma cells following daratumumab therapy, which interferes with CD38 detection for 4 to 6 months","volume":"153","author":"Courville","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqab163","article-title":"VS38c and CD38-multiepitope antibodies provide highly comparable minimal residual disease data in patients with multiple myeloma","volume":"157","author":"Broijl","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.735518","article-title":"Advanced flow cytometry analysis algorithms for optimizing the detection of \"Different from normal\" immunophenotypes in acute myeloid blasts","volume":"9","author":"Aanei","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cyto.b.22053","article-title":"Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis","volume":"102","author":"Soh","year":"2022","journal-title":"Cytom B Clin Cytom"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1057713\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T07:03:02Z","timestamp":1669618982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1057713\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":69,"alternative-id":["10.3389\/fonc.2022.1057713"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1057713","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"article-number":"1057713"}}